Home
  >  
Section 66
  >  
Chapter 65,908

Risk of fatigue in cancer patients treated with anti programmed cell death-1/anti programmed cell death ligand-1 agents: a systematic review and meta-analysis

Santoni, M.; Conti, A.; Buti, S.; Bersanelli, M.; Foghini, L.; Piva, F.; Giulietti, M.; Lusuardi, L.; Battelli, N.

ImmunoTherapy 10(15): 1303-1313

2018

ISSN/ISBN: 1750-743X
PMID: 30474475
DOI: 10.2217/imt-2018-0067
Accession: 065907715
Download citation:  
Text
  |  
BibTeX
  |  
RIS
We aimed to assess the incidence and relative risk (RR) of fatigue in cancer patients treated with anti programmed cell death-1 (PD-1) and anti programmed cell death ligand-1 (PD-L1) agents. Eligible studies were selected according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. Incidence, RR and 95% CIs were calculated using random or fixed-effects models. Thirty-eight studies were included in this analysis, with a total of 11,719 patients. The incidences were 23.4 and 2.1% for all- and high-grade fatigue, respectively. The highest incidence of high-grade fatigue was reported by the combination of nivolumab and ipilimumab. Overall RR of high-grade fatigue with anti-PD-1/PD-L1 compared with chemotherapy or targeted therapy was 0.48. Treatment with anti-PD-1/PD-L1 agents correlates with lower incidence and RR of fatigue compared with standard therapies.

PDF emailed within 0-6 h: $19.90




Related References

Le Burel, Sébastien.; Champiat, Séphane.; Mateus, C.; Marabelle, Aélien.; Michot, J-Marie.; Robert, C.; Belkhir, R.; Soria, J-Charles.; Laghouati, S.; Voisin, A-Laure.; Fain, O.; Mékinian, Aène.; Coutte, L.; Szwebel, T-Anne.; Dunogeant, L.; Lioger, B.; Luxembourger, Cécile.; Mariette, X.; Lambotte, O. 2017: Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis European Journal of Cancer 82: 34-44
Fouchard, M.; Jantzem, H.; Quere, G.; Descourt, R.; Robinet, G.; Poureau, P-Guillaume. 2019: Three cases of immune cholangitis related to anti-programmed cell death and programmed cell death ligand agents for the treatment of non-small cell lung cancer European Journal of Cancer 115: 107-110
Sun, X.; Roudi, R.; Dai, T.; Chen, S.; Fan, B.; Li, H.; Zhou, Y.; Zhou, M.; Zhu, B.; Yin, C.; Li, B.; Li, X. 2019: Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis Bmc Cancer 19(1): 558
Shang, H.; Zhang, Z.; Feng, A.; Yang, X.; Zhang, S.; Zhao, Y.; Zhu, Q.; Mao, Y.; Liu, K.; Tian, Y. 2019: The overall safety evaluation of programmed cell death/programmed cell death ligand 1 (PD-1/PD-L1) treatment for lung cancer patients: An updated systematic review and meta-analysis Medicine 98(30): E16439
Duan, J.; Cui, L.; Zhao, X.; Bai, H.; Cai, S.; Wang, G.; Zhao, Z.; Zhao, J.; Chen, S.; Song, J.; Qi, C.; Wang, Q.; Huang, M.; Zhang, Y.; Huang, D.; Bai, Y.; Sun, F.; Lee, J.Jack.; Wang, Z.; Wang, J. 2020: Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis JAMA Oncology 6(3): 375-384
Rizvi, H.; Sanchez-Vega, F.; La, K.; Chatila, W.; Jonsson, P.; Halpenny, D.; Plodkowski, A.; Long, N.; Sauter, J.L.; Rekhtman, N.; Hollmann, T.; Schalper, K.A.; Gainor, J.F.; Shen, R.; Ni, A.; Arbour, K.C.; Merghoub, T.; Wolchok, J.; Snyder, A.; Chaft, J.E.; Kris, M.G.; Rudin, C.M.; Socci, N.D.; Berger, M.F.; Taylor, B.S.; Zehir, A.; Solit, D.B.; Arcila, M.E.; Ladanyi, M.; Riely, G.J.; Schultz, N.; Hellmann, M.D. 2018: Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 36(7): 633-641
Khunger, M.; Rakshit, S.; Pasupuleti, V.; Hernandez, A.V.; Mazzone, P.; Stevenson, J.; Pennell, N.A.; Velcheti, V. 2017: Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials Chest 152(2): 271-281
Rivera, N.; Boada, A.; Bielsa, M.Isabel.; Fernández-Figueras, M.Teresa.; Carcereny, E.; Moran, M.Teresa.; Ferrándiz, C. 2017: Hair Repigmentation During Immunotherapy Treatment With an Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Agent for Lung Cancer JAMA Dermatology 153(11): 1162-1165
Bernard-Tessier, A.; Baldini, C.; Martin, P.; Champiat, Séphane.; Hollebecque, A.; Postel-Vinay, S.; Varga, A.; Bahleda, R.; Gazzah, A.; Michot, J-Marie.; Ribrag, V.; Armand, J-Pierre.; Marabelle, Aélien.; Soria, J-Charles.; Massard, C. 2018: Outcomes of long-term responders to anti-programmed death 1 and anti-programmed death ligand 1 when being rechallenged with the same anti-programmed death 1 and anti-programmed death ligand 1 at progression European Journal of Cancer 101: 160-164
Pattanaik, S.; Dey, S.; Jaiswal, N.; Rohilla, R.; Singh, S.Kumar.; Mandal, A.Kumar.; Mavuduru, R.Suryanarayan. 2019: Efficacy and safety of programmed cell death-1/programmed cell death ligand-1 inhibitors in advanced urothelial malignancy: A systematic review and meta-analysis Indian Journal of Urology: Iju: Journal of the Urological Society of India 35(2): 101-115
Zhang, Q.; Qi, Z.; Bo-Liu; Li, C-Sheng. 2018: Programmed Cell Death-1/Programmed Death-Ligand 1 Blockade Improves Survival of Animals with Sepsis: A Systematic Review and Meta-Analysis Biomed Research International 2018: 1969474
Shen, J.; Chang, J.; Mendenhall, M.; Cherry, G.; Goldman, J.W.; Kulkarni, R.P. 2018: Diverse cutaneous adverse eruptions caused by anti-programmed cell death-1 (PD-1) and anti-programmed cell death ligand-1 (PD-L1) immunotherapies: clinical features and management Therapeutic Advances in Medical Oncology 10: 1758834017751634
Lazarus, G.; Audrey, J.; Iskandar, A.William.Brian. 2019: Efficacy and safety profiles of programmed cell death-1/programmed cell death ligand-1 inhibitors in the treatment of triple-negative breast cancer: A comprehensive systematic review Oncology Reviews 13(2): 425
Shi, V.J.; Rodic, N.; Gettinger, S.; Leventhal, J.S.; Neckman, J.P.; Girardi, M.; Bosenberg, M.; Choi, J.N. 2016: Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Immunotherapy JAMA Dermatology 152(10): 1128-1136
Ilie, M.; Juco, J.; Huang, L.; Hofman, V.; Khambata-Ford, S.; Hofman, P. 2018: Use of the 22C3 anti-programmed death-ligand 1 antibody to determine programmed death-ligand 1 expression in cytology samples obtained from non-small cell lung cancer patients Cancer Cytopathology 126(4): 264-274
Choi, F.D.; Kraus, C.N.; Elsensohn, A.N.; Carley, S.K.; Lehmer, L.M.; Nguyen, R.T.; Linden, K.G.; Shiu, J. 2020: Programmed cell death 1 protein and programmed death-ligand 1 inhibitors in the treatment of nonmelanoma skin cancer: A systematic review Journal of the American Academy of Dermatology 82(2): 440-459
Niglio, S.A.; Jia, R.; Ji, J.; Ruder, S.; Patel, V.G.; Martini, A.; Sfakianos, J.P.; Marqueen, K.E.; Waingankar, N.; Mehrazin, R.; Wiklund, P.; Oh, W.K.; Mazumdar, M.; Ferket, B.S.; Galsky, M.D. 2019: Programmed Death-1 or Programmed Death Ligand-1 Blockade in Patients with Platinum-resistant Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis European Urology 76(6): 782-789
Zhao, C.Yunjia.; Consuegra, G.; Chou, S.; Fernández-Peñas, P. 2017: Intracorneal pustular drug eruption, a novel cutaneous adverse event in anti-programmed cell death-1 patients that highlights the effect of anti-programmed cell death-1 in neutrophils Melanoma research 27(6): 641-644
Gao, Y.; Li, S.; Xu, D.; Chen, S.; Cai, Y.; Jiang, W.; Zhang, X.; Sun, J.; Wang, K.; Chang, B.; Wang, F.; Hong, M. 2017: Prognostic value of programmed death-1, programmed death-ligand 1, programmed death-ligand 2 expression, and CD8(+) T cell density in primary tumors and metastatic lymph nodes from patients with stage T1-4N+M0 gastric adenocarcinoma Chinese Journal of Cancer 36(1): 61
Nie, W.; Xu, M-D.; Gan, L.; Zhang, Y.; Han, B-H. 2019: Advanced non-small cell lung cancer patients with low tumor mutation burden might derive benefit from anti-programmed cell death (PD)-1 and anti-programmed deathligand 1 (PD-L1) blockade Annals of Oncology: Official Journal of the European Society for Medical Oncology 30 Suppl. 2: Ii62